Clinical Trials Browser

Terminated × OTHER × Brentuximab Vedotin × Clear all

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

1 enrolled 3 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT02499627 2021-05-27

FIL-BBV

Phase 2 Terminated

Lymphatic Diseases, Lymphoma

NCT02988843 2020-12-10

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Phase 2 Terminated

1 enrolled 8 charts

Neoplasms, Germ Cell and Embryonal

NCT02254239 2019-12-12

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1 Terminated

Hodgkin Disease

NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Phase 2 Terminated

18 enrolled 13 charts

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT02169505 2019-11-27

Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Phase 2 Terminated

2 enrolled 5 charts

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT01841021 2017-01-19

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Phase NA Terminated

1 enrolled 5 charts

Recurrence, Lymphoma, T-Cell, Peripheral